AstraZeneca Competitors

AZNCF Stock

USD 157.45 14.32 6.24%

AstraZeneca PLC competes with Roche Holding, Roche Holding, Roche Holding, Grifols SA, and Astellas Pharma; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. Analyzing AstraZeneca PLC competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of AstraZeneca PLC to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of AstraZeneca PLC competition on your existing holdings.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AstraZeneca PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.

Hype

Prediction

Low	Estimated	High
131.58	133.93	136.28

Details

Intrinsic

Valuation

Low	Real	High
116.84	119.19	147.32

Details

Naive

Forecast

Low	Next	High
137.29	139.63	141.98

Details

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
123.89	131.31	138.73

Details

AstraZeneca PLC Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AstraZeneca PLC and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of AstraZeneca and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AstraZeneca PLC does not affect the price movement of the other competitor.

	RHHVF	RHHBF	RHHBY	GRFS	BAYZF	ALPMF	ALPMY	BAYRY	BMYMP	DSKYF
RHHVF		0.79	0.77	-0.04	0.58	0.45	0.83	-0.24	-0.44	0.58	RHHVF
RHHBF	0.79		0.69	0.01	0.34	0.47	0.65	-0.16	-0.28	0.43	RHHBF
RHHBY	0.77	0.69		-0.08	0.72	0.63	0.67	-0.43	-0.57	0.67	RHHBY
GRFS	-0.04	0.01	-0.08		-0.08	0.01	0.06	0.18	0.02	0.14	GRFS
BAYZF	0.58	0.34	0.72	-0.08		0.59	0.68	-0.57	-0.83	0.6	BAYZF
ALPMF	0.45	0.47	0.63	0.01	0.59		0.56	-0.67	-0.56	0.51	ALPMF
ALPMY	0.83	0.65	0.67	0.06	0.68	0.56		-0.3	-0.56	0.68	ALPMY
BAYRY	-0.24	-0.16	-0.43	0.18	-0.57	-0.67	-0.3		0.51	-0.34	BAYRY
BMYMP	-0.44	-0.28	-0.57	0.02	-0.83	-0.56	-0.56	0.51		-0.44	BMYMP
DSKYF	0.58	0.43	0.67	0.14	0.6	0.51	0.68	-0.34	-0.44		DSKYF
	RHHVF	RHHBF	RHHBY	GRFS	BAYZF	ALPMF	ALPMY	BAYRY	BMYMP	DSKYF

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

ALPMY	+ 0.83	RHHVF
RHHBF	+ 0.79	RHHVF
RHHBY	+ 0.77	RHHVF
BAYZF	+ 0.72	RHHBY
RHHBY	+ 0.69	RHHBF
ALPMY	+ 0.68	BAYZF

High negative correlations

BMYMP	- 0.83	BAYZF
BAYRY	- 0.67	ALPMF
BAYRY	- 0.57	BAYZF
BMYMP	- 0.57	RHHBY
BMYMP	- 0.56	ALPMY
BMYMP	- 0.56	ALPMF

Risk-Adjusted Indicators

There is a big difference between AstraZeneca Pink Sheet performing well and AstraZeneca PLC Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AstraZeneca PLC's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
RHHVF	1.15	(0.23)	0.00	(1.97)	0.00	0.00	1.79	(2.72)	5.43
RHHBF	1.79	(0.28)	0.00	2.90	0.00	0.00	3.03	(5.55)	16.69
RHHBY	0.99	(0.30)	0.00	(0.64)	0.00	0.00	1.20	(2.76)	7.58
GRFS	1.88	(0.01)	(0.05)	0.09	2.21	(2.53)	5.06	(4.39)	17.76
BAYZF	1.62	(0.58)	0.00	(23.38)	0.00	0.00	3.32	(4.23)	21.44
ALPMF	1.43	(0.35)	0.00	(0.36)	0.00	0.00	4.36	(7.25)	20.76
ALPMY	1.23	(0.30)	0.00	(6.80)	0.00	0.00	2.11	(3.45)	10.71
BAYRY	1.32	0.48	0.25	6.82	0.98	(1.60)	3.93	(1.62)	8.67
BMYMP	1.58	0.46	0.00	3.44	0.00	0.00	3.84	(0.07)	21.01
DSKYF	5.19	(0.32)	0.00	(1.27)	0.00	0.00	10.11	(8.60)	25.21

Unable to evaluate fundamental data of [RHHVF, RHHBF, RHHBY, GRFS, BAYZF, ALPMF, ALPMY, BAYRY, BMYMP, DSKYF, NVSEF, SNY] at this time. Please try again later

All Fundamental Data

AstraZeneca PLC Competitive Analysis

The better you understand AstraZeneca PLC competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AstraZeneca PLC's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AstraZeneca PLC's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	AZNCF	RHHVF	RHHBF	RHHBY	GRFS	BAYZF	ALPMF	ALPMY	BAYRY	BMYMP
	6.24 133.93 AstraZeneca	0.67 287.04 Roche	0.88 288.23 Roche	0.43 35.44 Roche	1.87 8.70 Grifols	1.71 20.81 Bayer	0.72 9.68 Astellas	0.39 10.09 Astellas	5.37 16.86 Bayer	0.00 1,006 Bristol-Myers
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Somewhat reliable	Not too volatile	Somewhat reliable	Not too volatile	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak	OK
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Low	Low	Low	Low	Low	Low	Low	Dangerous	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Over Valued	Over Valued	Over Valued	Under Valued	Fairly Valued	Over Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Cautious Hold	Cautious Hold	Strong Sell	Hold	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Not Rated	Cautious Hold
Current Ratio	0.96	1.11	1.11	1.11	2.68	1.18	1.34	1.34	1.16	1.4
Net Asset	96.48 B	92.32 B	92.32 B	92.32 B	21.45 B	120.24 B	2.33 T	2.33 T	120.24 B	109.31 B
Profit Margin	0.0741	0.19	0.19	0.19	0.0231	0.0943	0.0929	0.0929	0.0943	N/A
EBITDA	9.33 B	22.26 B	22.26 B	22.26 B	1.18 B	6.45 B	241.52 B	241.52 B	6.45 B	20.1 B
Operating Margin	0.19	0.32	0.32	0.32	0.2	0.23	0.17	0.17	0.23	N/A
Current Valuation	241.1 B	287.91 B	287.91 B	293.22 B	15.7 B	87.41 B	26.19 B	26.19 B	87.41 B	N/A
Price To Book	6.16	9.57	11.61	9.81	1.06	1.36	2.38	2.44	1.36	N/A
Retained Earnings	6.38 B	25.51 B	25.51 B	N/A	59.31 M	N/A	941.23 B	941.23 B	N/A	N/A
Current Asset	12.87 B	26.61 B	26.61 B	28.15 B	3.09 B	25.17 B	874.69 B	874.69 B	25.17 B	N/A
Five Year Return	3.01	3.23	3.23	2.98	2.33	4.07	2.25	2.39	4.08	N/A
Beta	0.19	0.19	0.19	0.19	0.69	1.17	0.51	0.51	1.17	0.35
Number Of Employees	42	103.61 K	103.61 K	103.61 K	23 K	102.3 K	14.52 K	14.52 K	102.3 K	23.7 K
Shares Outstanding	1.55 B	693.89 M	106.69 M	6.4 B	257.44 M	982.42 M	1.83 B	1.83 B	3.93 B	N/A
Cash Flow From Operations	9.81 B	20.98 B	20.98 B	20.98 B	208.28 M	5.09 B	257.44 B	257.44 B	5.09 B	16.21 B
Annual Yield	0.0205	0.034	0.0291	0.0338	N/A	0.0332	0.032	0.0285	0.033	0.0012
Total Debt	22.96 B	16.08 B	16.08 B	16.08 B	10.12 B	35.55 B	4.87 B	4.87 B	35.55 B	39.6 B
Return On Equity	0.0863	0.45	0.45	0.45	0.0271	0.13	0.0898	0.0898	0.13	N/A
Z Score	5.4	9.0	9.0	9.0	N/A	0.6	3.0	3.0	0.6	N/A
Return On Asset	0.0531	0.15	0.15	0.15	0.0287	0.0576	0.0653	0.0653	0.0576	N/A
Book Value Per Share	23.91	35.03	35.03	4.38	7.87	42.01	861.58	861.58	10.5	7.55
Number Of Shares Shorted	N/A	N/A	N/A	N/A	4.17 M	N/A	N/A	N/A	N/A	N/A
Current Liabilities	15.38 B	24.46 B	24.46 B	23.74 B	1.05 B	16.68 B	383.53 B	383.53 B	16.68 B	N/A
Total Asset	96.48 B	92.32 B	92.32 B	92.32 B	21.45 B	120.24 B	2.33 T	2.33 T	120.24 B	109.31 B
Debt To Equity	0.87	1.0	1.0	1.0	1.14	1.17	0.003	0.003	1.08	59.4
Last Dividend Paid	2.9	9.5	9.5	9.5	N/A	2.0	25.0	25.0	2.0	1.59
Target Price	N/A	423.65	423.65	47.8	10.67	N/A	50.0	15.38	15.0	N/A
Short Ratio	N/A	N/A	N/A	N/A	7.07	N/A	N/A	N/A	N/A	N/A
Shares Owned By Institutions	48.84	40.3	8.56	1.27	58.25	47.11	50.43	0.03	0.1	N/A
Market Capitalization	215.86 B	241.38 B	246.23 B	244.36 B	7.13 B	64.24 B	26.66 B	26.53 B	64.01 B	2.11 T
Price To Earning	44.18	18.04	21.63	17.56	14.34	321.83	25.09	25.98	12.46	N/A
Price To Earnings To Growth	1.37	3.44	4.18	3.53	0.23	1.31	N/A	N/A	1.31	N/A
Price To Sales	4.73	3.97	4.11	3.99	0.99	1.06	0.0208	0.0208	1.02	N/A
Net Income	3.29 B	13.93 B	13.93 B	13.93 B	59.31 M	1000 M	124.09 B	124.09 B	1000 M	7.01 B
Earnings Per Share	2.11	19.18	19.18	2.4	0.26	5.13	0.57	0.57	1.28	N/A
Shares Owned By Insiders	0.22	N/A	75.31	N/A	N/A	N/A	0.37	N/A	N/A	N/A
Revenue	44.35 B	62.8 B	62.8 B	62.8 B	6.59 B	44.08 B	1.3 T	1.3 T	44.08 B	46.38 B
Working Capital	(2.52 B)	2.16 B	2.16 B	4.41 B	4.14 B	8.49 B	491.17 B	491.17 B	8.49 B	N/A
Cash And Equivalents	4.89 B	6.81 B	6.81 B	6.81 B	549.09 M	8.19 B	336.76 B	336.76 B	9.07 B	6.07 B
Cash Per Share	3.15	8.5	8.5	1.06	0.4	8.34	184.77	184.77	2.31	3.72
Gross Profit	35.73 B	47.83 B	47.83 B	47.83 B	2.23 B	27.04 B	1.04 T	1.04 T	27.04 B	N/A
Day Typical Price	132.47	285.28	293.82	35.49	8.64	20.68	9.68	9.98	16.55	1005.55
Accumulation Distribution	0.0327	0.0184	0.055	0.007	0.0443	0.0206	N/A	0.0376	0.0609	N/A
Market Facilitation Index	4.38	5.28	16.77	0.25	0.39	0.43	N/A	0.38	1.03	N/A
Daily Balance Of Power	1.796804	0.3598	0.1503	0.6	0.4103	0.814	(9,223,372,036,855)	(0.11)	0.835	0.0
Period Momentum Indicator	7.87	1.9	2.52	0.15	0.16	0.35	(0.07)	(0.04)	0.86	N/A
Rate Of Daily Change	1.06	1.01	1.01	1.0	1.02	1.02	0.99	1.0	1.05	1.0
Day Median Price	131.74	284.4	296.62	35.52	8.62	20.62	9.68	9.92	16.4	1005.55
Price Action Indicator	6.13	3.59	(7.12)	N/A	0.16	0.37	(0.04)	0.15	0.89	N/A
Relative Strength Index	18.94	36.34	35.12	38.18	64.77	33.1	41.02	42.89	66.32	81.22
Coefficient Of Variation	(665.31)	(664.52)	(969.90)	(576.30)	10580.03	(490.80)	(1,171)	(589.97)	375.37	716.49
Mean Deviation	1.7	1.15	1.79	0.9908	1.88	1.62	1.43	1.23	1.32	1.58
Jensen Alpha	(0.47)	(0.23)	(0.28)	(0.30)	(0.01)	(0.58)	(0.35)	(0.30)	0.4795	0.4608
Total Risk Alpha	(0.73)	(0.44)	(0.72)	(0.48)	(0.42)	(1.02)	(0.72)	(0.57)	0.1937	(0.07)
Sortino Ratio	N/A	N/A	N/A	N/A	(0.05)	N/A	N/A	N/A	0.2489	N/A
Downside Variance	N/A	N/A	N/A	N/A	5.19	N/A	N/A	N/A	2.18	N/A
Standard Deviation	2.35	1.39	2.74	1.41	2.74	2.8	2.92	1.7	1.87	3.49
Kurtosis	1.68	(0.53)	2.11	4.25	2.82	9.08	6.37	2.07	2.12	11.45
Potential Upside	2.65	1.79	3.03	1.2	5.06	3.32	4.36	2.11	3.93	3.84
Treynor Ratio	(0.42)	(1.97)	2.9	(0.64)	0.0911	(23.38)	(0.36)	(6.80)	6.82	3.44
Maximum Drawdown	12.29	5.43	16.69	7.58	17.76	21.44	20.76	10.71	8.67	21.01
Variance	5.53	1.94	7.5	2.0	7.52	7.82	8.51	2.88	3.5	12.2
Market Risk Adjusted Performance	(0.41)	(1.96)	2.91	(0.63)	0.1011	(23.37)	(0.35)	(6.79)	6.83	3.45
Risk Adjusted Performance	(0.11)	(0.11)	(0.07)	(0.13)	0.0145	(0.15)	(0.06)	(0.12)	0.2102	0.1148
Skewness	(0.44)	(0.35)	(0.14)	(1.00)	0.6153	(1.61)	(1.25)	0.2001	0.7685	2.14
Semi Deviation	N/A	N/A	N/A	N/A	2.21	N/A	N/A	N/A	0.9829	N/A
Information Ratio	(0.21)	(0.24)	(0.15)	(0.27)	(0.04)	(0.25)	(0.13)	(0.25)	0.1965	0.1021
Value At Risk	(4.54)	(2.72)	(5.55)	(2.76)	(4.39)	(4.23)	(7.25)	(3.45)	(1.62)	(0.07)
Expected Short fall	N/A	N/A	N/A	N/A	(2.53)	N/A	N/A	N/A	(1.60)	N/A
Downside Deviation	N/A	N/A	N/A	N/A	2.28	N/A	N/A	N/A	1.48	N/A
Semi Variance	N/A	N/A	N/A	N/A	4.9	N/A	N/A	N/A	0.9661	N/A

AstraZeneca PLC Competition Performance Charts

Five steps to successful analysis of AstraZeneca PLC Competition

AstraZeneca PLC's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AstraZeneca PLC in relation to its competition. AstraZeneca PLC's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of AstraZeneca PLC in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AstraZeneca PLC's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AstraZeneca PLC, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your AstraZeneca PLC position

In addition to having AstraZeneca PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Books Thematic Idea Now

Books

Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 47 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in AstraZeneca Pink Sheet

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Competitors

Specify up to 10 symbols:

AstraZeneca PLC Competition Correlation Matrix

Risk-Adjusted Indicators

AstraZeneca PLC Competitive Analysis

AstraZeneca PLC Competition Performance Charts

Five steps to successful analysis of AstraZeneca PLC Competition

Complement your AstraZeneca PLC position

Did You Try This Idea?

Run Books Thematic Idea Now

Books

Other Information on Investing in AstraZeneca Pink Sheet

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY